ArticleFrontiers in public health2025
The impacts of diagnosis-intervention packet payment on inpatient medical costs for hematologic malignancies and solid tumors: evidence from a retrospective study in China.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to analyze and compare the impact of the diagnosis-intervention packet (DIP) payment on inpatient medical costs for hematologic malignancies (HM) and solid tumors (ST) patients, and to explore its implications for hospital financial sustainability and payment reform. Methods: Using a retrospective research design, this study focused on HM and ST patients treated before and after the implementation of the DIP payment at a large tertiary general hospital in A city, located in the eastern coastal area of China. Data were collected, organized, and analyzed to compare differences in inpatient medical costs between HM and ST patients and to examine their impact on the income of the department of hematology. Results: The study included 5,115 cases from both before and after the DIP payment implementation. Post-implementation, the median inpatient medical costs per case decreased from 5,544.45 CNY to 5,169.66 CNY, with costs for both HM and ST hospitalizations showing a decline. Specifically, the inpatient medical costs per case for HM were 5,722.46 (4,471.08, 11,508.78) CNY, higher than those for ST at 4,779.28 (3,056.70, 7,152.64) CNY, and exceeding the DIP payment standard. Wilcoxon signed-rank test and regression analysis indicated that HM inpatient medical costs surpass the standard payments, resulting in financial losses. All findings were statistically significant ( Conclusion: Despite a reduction in median inpatient medical costs following the implementation of the DIP payment, departments treating HM patients continue to experience financial losses due to costs exceeding the payment standard. These findings highlight the need to refine DIP payment standards to better account for clinical complexity and technological advancements. Future reforms should aim to improve alignment between payments and actual care needs to ensure financial sustainability and equity. However, this study is limited by its single-center design and lack of control for potential confounders. Broader multi-center studies with more detailed clinical data are needed to validate and extend these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.